Novel Patent Targets the Most Common Sleep Complaint: Chronic Insomnia

CLEVELAND--(EON: Enhanced Online News)--Consolidated Research of Richmond, Inc. (CRI) announces the awarding of United States Patent 7,654,948 - which is a novel, drug-free system for treating people suffering from the most common sleep complaint: Chronic Insomnia. An estimated 10-20% of the industrialized world’s adult population suffers from moderate to severe chronic insomnia, yet, unlike sleep apnea, there is a significant lack of technology addressing this tremendous need. Products based on Consolidated Research's patented technologies will address this market need.

About CRI -- Consolidated Research of Richmond, Inc. is a privately held engineering research and development firm based in Northeast Ohio. Areas of technical expertise include: signal processing; mathematical and computer modeling; real-time algorithm development; and microelectronic design. For over 15 years, CRI has focused on the development of unique technologies for the sleep and intraoperative monitoring markets. CRI’s latest development is an innovative technology package that enables a new class of highly effective and easy-to-use devices for the treatment of chronic insomnia.